Phaseline

Companies › Eureka Therapeutics

Eureka Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ECT204
GPC3-targeted autologous T-cell therapy (CAR-T cell therapy)
–Phase 1Hepatocellular CarcinomaDec 2027
ET140203 T Cells
Autologous T cells expressing TCR targeting AFP
–Phase 1HepatoblastomaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04634357ET140203 T CellsPhase 1HepatoblastomaOncologyDec 2027
NCT04864054ECT204Phase 1Hepatocellular CarcinomaOncologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.